Partial
Needs Improvement
Patient Risk:
Low
Summary
Most statements are about generic launch timing/availability and generic referencing expectations, which are not addressed in the provided FDA prescribing information excerpts. The only label-relevant statement (active ingredient identity) is supported by the labeling excerpt’s drug definition (bimatoprost).
Category Scores
Accurate Statements
Lumigan's generic active ingredient is bimatoprost (ophthalmic solution).
Supported by the provided label excerpt identifying LUMIGAN as bimatoprost ophthalmic solution (Sections 1 and 12.1).
Any generic is expected to reference the same active ingredient as Lumigan and match strength and route to the brand's listed product.
Partially supported only insofar as the label excerpt specifies LUMIGAN’s active ingredient/route (bimatoprost ophthalmic solution; Sections 1 and drug/label context). The excerpt does not explicitly address generic reference/bioequivalence expectations.
Unsupported Statements
Lumigan became available as a generic medicine after its brand exclusivity ended.
Not supported or mentioned in the provided prescribing information excerpts (Sections 1, 2, 4, 5, 6, 8, 10, 12, 14).
Approved generic versions entered the market after Lumigan's brand exclusivity ended.
Not supported or mentioned in the provided prescribing information excerpts.
The exact first generic launch date depends on the specific generic manufacturer.
Not supported or mentioned in the provided prescribing information excerpts.
The exact first generic launch date depends on whether you mean the approval date versus when products actually appeared for sale in the U.S.
Not supported or mentioned in the provided prescribing information excerpts.
Generic availability timelines can be based on an FDA approval date when a generic is approved to be marketed.
Not supported or mentioned in the provided prescribing information excerpts.
Generic availability timelines can be based on a launch/availability date when the generic is stocked by wholesalers and pharmacies.
Not supported or mentioned in the provided prescribing information excerpts.
Contradictions
Important Omissions
Any label-relevant content (indication, dosing schedule, contraindications, warnings/precautions, adverse reactions, or specific population guidance) corresponding to the safety/clinical aspects of LUMIGAN®.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The statements evaluated are primarily about generic availability/timing and do not claim patient-specific dosing, contraindications, or safety outcomes. The only label-relevant claim about active ingredient identity is supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Improvement
Primary Issue
Most claims are not addressed by the provided prescribing information excerpts, which prevents label-based verification; only the active ingredient identity aligns with the provided label text.
Suggested Improvement
Limit claims to content present in the provided FDA-approved prescribing information (e.g., indication, dosing, contraindications, warnings/precautions, adverse reactions). If discussing generic availability/launch dates, cite sources beyond the prescribing information or avoid making unverifiable timing claims.